Milton C Ault III sold $227k of ALZN
director, owner at Alzamend Neuro, Inc.. 97,006 shares at an average of $2.34, traded Sep 23, 2025, filed Sep 25, 2025.
Score components
- +15RoleDirector
- +13Trade size$227k at market
- +20Share of holdings soldSold 90% of holdings
- 0ClusterNo other insider selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m +5.5%, 3m -13.1%, 6m -36.4%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001214659-25-014210, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Sep 23, 2025 | SOpen-market sale Common Stockindirect: By Ault Lending, LLC | -43,238 | $2.38 | $103k | 65,022 | Sep 25, 2025 |
| Sep 24, 2025 | SOpen-market sale Common Stockindirect: By Ault Lending, LLC | -39,140 | $2.31 | $90k | 25,882 | Sep 25, 2025 |
| Sep 25, 2025 | SOpen-market sale Common Stockindirect: By Ault Lending, LLC | -14,628 | $2.31 | $34k | 11,254 | Sep 25, 2025 |
| Sep 25, 2025 | CConversion Common Stockindirect: By Ault Lending, LLC | +100,000 | $2.32 | $232k | 111,254 | Sep 25, 2025 |
| Sep 25, 2025 | CConversion Series B Convertible Preferred Stockderivativeindirect: By Ault Lending, LLC | -232 | $1,000.00 | $232k | 839 | Sep 25, 2025 |
Related signals
Other insiders at Alzamend Neuro, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 35Weak | ALZNsell Alzamend Neuro, Inc. | Milton C Ault III director | $3,116 2,000 shares | -100% | |
| 38Weak | ALZNbuy Alzamend Neuro, Inc. | Milton C Ault III director | $111k 110,388 shares | +1336% | |
| 38Weak | ALZNbuy Alzamend Neuro, Inc. | Milton C Ault III director | $111k 110,388 shares | +1336% | |
| 38Weak | ALZNbuy Alzamend Neuro, Inc. | Milton C Ault III director | $109k 108,388 shares | +1312% | |
| 43Moderate | Alzamend Neuro, Inc. | Milton C Ault III director | $3,825 1,851 shares | -100% | |
| 43Moderate | Alzamend Neuro, Inc. | William B. Horne director | $7,059 3,333 shares | -100% | |
| 35Weak | ALZNsell Alzamend Neuro, Inc. | Lynne Fahey McGrath director | $69 30 shares | -55% | |
| 49Moderate | ALZNsell Alzamend Neuro, Inc. | Milton C Ault III director | $295k 121,791 shares | -94% | |
| 50Moderate | ALZNsell Alzamend Neuro, Inc. | Milton C Ault III director | $344k 139,412 shares | -129% | |
| 49Moderate | ALZNsell Alzamend Neuro, Inc. | Milton C Ault III director | $297k 123,366 shares | -94% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.